SOLIRIS® - (Eculizumab) Products
SOLIRIS® is a first-in-class terminal complement inhibitor which works by electively inhibiting activation of specific proteins in the complement system (c5 and c5b), which play a role in the treatment of multiple rare diseases.1
Nufactor carries SOLIRIS (Eculizumab):
Product
Manufacturer
FDA-Approved Indication
IMMUNOSUPPRESSANT
Product: SOLIRIS® (Eculizumab)
Manufacturer: Alexion
FDA-Approved Indication:
Generalized myasthenia gravis (gMG),
Paroxysmal nocturnal hemoglobinuria (PNH),
Atypical hemolytic uremic syndrome (aHUS),
Neuromyelitis optica spectrum disorder (NMOSD)
Paroxysmal nocturnal hemoglobinuria (PNH),
Atypical hemolytic uremic syndrome (aHUS),
Neuromyelitis optica spectrum disorder (NMOSD)
1 Alexion Pharmaceuticals. Soliris® (Eculizumab). Alexion.com/products/Soliris
Click here for a SOLIRIS (Eculizumab) order form.
